Vascular endothelial growth factor in human preterm lung

Area of Science:

• Neonatal Medicine
• Pulmonary Biology
• Vascular Biology

Background:

• Endothelial cell damage is a hallmark of respiratory distress syndrome and chronic lung disease in preterm infants.
• Vascular endothelial growth factor (VEGF) is crucial for endothelial cell growth, repair, and vascular development.

Purpose of the Study:

• To investigate the levels and trends of VEGF in tracheal aspirate fluid (TAF) and plasma of intubated preterm infants during the first postnatal week.
• To explore the relationship between VEGF levels and maternal factors, gestational age, birth weight, pulmonary maturity, and the development of bronchopulmonary dysplasia (BPD).

Main Methods:

• VEGF concentrations were measured in TAF and plasma samples from 44 intubated preterm infants.
• Data were collected during the first postnatal week, correlating VEGF levels with clinical data and maternal history.

Main Results:

• TAF VEGF concentrations significantly increased from Day 1 to Day 7 postnatally.
• Plasma VEGF levels remained stable without a significant increase during the first week.
• Higher TAF VEGF was associated with maternal premature rupture of membranes or chorioamnionitis, while lower VEGF correlated with maternal preeclampsia.
• Lower TAF VEGF levels were observed in infants who developed bronchopulmonary dysplasia (BPD).

Conclusions:

• VEGF levels increase in the lungs of preterm infants during the early postnatal period.
• TAF VEGF may serve as an indicator of pulmonary maturity and play a role in lung repair following acute lung injury.
• VEGF levels are influenced by maternal conditions and are associated with the risk of developing BPD.